Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | LIPC | P11150 | 1/20 | 0.30 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647136 | 0.90 | CHRNA7 (0.34) | ACHECYP19A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL3917894 | 0.86 | TRPV3 (0.34) | ACHECYP19A1CYP11B1CYP11B2HSD17B10 | |
| SCHEMBL647168 | 0.85 | CHRNA7 (0.34) | ACHECYP19A1CYP11B1CYP11B2MEN1 | |
| SCHEMBL646575 | 0.85 | CYP19A1 (0.35) | CYP19A1CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL649401 | 0.85 | ACHE (0.34) | ACHEMEN1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL3918925 | 0.84 | CHRNA7 (0.33) | CYP19A1CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL648847 | 0.84 | PTGER1 (0.33) | CYP19A1CYP11B1CYP11B2HSD17B10ALDH1A1 | |
| SCHEMBL3928633 | 0.84 | CYP19A1 (0.35) | ACHECYP19A1CYP11B1CYP11B2HSD17B10 | |
| SCHEMBL649516 | 0.84 | MTNR1A (0.35) | ACHECYP19A1CYP11B1CYP11B2HSD17B10 | |
| SCHEMBL3927311 | 0.83 | CYP19A1 (0.36) | ACHECYP19A1CYP11B1CYP11B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963294-B1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1963294-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067613-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | ACHE 1561/4885CYP19A1 1947/4885CYP11B1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.